FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says
Executive Summary
FDA Commissioner McClellan's plan to accelerate drug development is "the single most encouraging story now emerging in our field," Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4